Represents a contingent liability that has not been recognized because it is not both estimable and probable.

No definition available.

Name:	anip_ContingentLiabilityNotRecognized
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents cumulative amortization expense related to transaction.

+ References

No definition available.

+ Details

Name:	anip_CumulativeAmortizationExpense
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

+ References

No definition available.

+ Details

Name:	anip_FairValuesInputsDiscountRate
Namespace Prefix:	anip_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of approved products under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfApprovedProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of approved products with launches pending under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfApprovedProductsWithLaunchesPendingUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of commercial products under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfCommercialProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of filed products under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfFiledProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of generic drug products.

+ References

No definition available.

+ Details

Name:	anip_NumberOfGenericDrugProducts
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of in-development products under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfInDevelopmentProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of years for the amount payable on the contingent profit share.

+ References

No definition available.

+ Details

Name:	anip_NumberOfYearsContingentProfitSharePayable
Namespace Prefix:	anip_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_InventoryFinishedGoods
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_InventoryNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_InventoryRawMaterials
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_LongtermPurchaseCommitmentPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

+ Details

Name:	us-gaap_PropertyPlantAndEquipmentFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name:	us-gaap_PropertyPlantAndEquipmentUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_MarketingAndDistributionRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_PrivateCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_AmerigenPharmaceuticalsLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_CoeptisPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_PharmaceuticsInternationalIncAndBasAndaLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_TevaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_ImpaxLaboratoriesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=anip_MilestoneOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=anip_MilestoneTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=anip_MilestoneThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

FAIR VALUE DISCLOSURES - Acquired (Details) $ in Thousands	1 Months Ended							3 Months Ended			9 Months Ended
FAIR VALUE DISCLOSURES - Acquired (Details) $ in Thousands	Jul. 31, 2020 USD ($)	May 31, 2020 USD ($) product	Jan. 31, 2020 USD ($) product	Jun. 30, 2019 USD ($) product	Mar. 31, 2019 USD ($) product	Jan. 31, 2019 USD ($)	Apr. 30, 2018 USD ($) product	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)
Payments to Acquire Intangible Assets											$ 62,178	$ 21,243
Finite-Lived Intangible Assets, Gross								$ 355,670	$ 307,225		355,670
Research and development								2,939		$ 4,982	12,318	15,128
Intangible asset impairment charge								0		0	0	0
Amortization of Intangible Assets								10,100		$ 8,400	30,200	31,800
Inventories, net								59,195	48,163		59,195
Raw materials								43,010	34,881		43,010
Finished goods								18,110	16,750		18,110
Research and Development in Process											3,753	$ 2,653
Acquired ANDA intangible assets
Finite-Lived Intangible Assets, Gross								106,415	64,704		$ 106,415
Finite-Lived Intangible Asset, Useful Life											8 years 9 months 18 days
Marketing and distribution rights
Finite-Lived Intangible Assets, Gross								$ 17,657	10,923		$ 17,657
Finite-Lived Intangible Asset, Useful Life											5 years 8 months 12 days
Private Company [Member]
Number of generic products \| product		1
Total asset purchase	$ 4,300	$ 200
Transaction costs	100	$ 7
Finite-Lived Intangible Assets, Gross	$ 3,000
Finite-Lived Intangible Asset, Useful Life	7 years	7 years
Intangible asset impairment charge											$ 0
Inventories, net	$ 1,400
Amerigen Pharmaceuticals, Ltd.
Number of generic products \| product			23
Total asset purchase			$ 56,800
Transaction costs			700
Contingent liability not recognized			$ 25,000
Period of contingent payments			4 years
Number of commercial products under product portfolio			10
Number of approved products with launches pending under product portfolio			3
Number of filed products under product portfolio			4
Number of in-development products under product portfolio			4
Number of approved products under product portfolio			2
Finite-Lived Intangible Asset, Useful Life			7 years
Research and development			$ 3,800
Intangible asset impairment charge											0
Inventories, net			8,400
Raw materials			1,700
Finished goods			$ 6,700
Amerigen Pharmaceuticals, Ltd. \| Discount rate
Fair Values Inputs Discount Rate			8.00%
Amerigen Pharmaceuticals, Ltd. \| Acquired ANDA intangible assets
Finite-Lived Intangible Assets, Gross			$ 38,500
Amerigen Pharmaceuticals, Ltd. \| Marketing and distribution rights
Finite-Lived Intangible Assets, Gross			$ 6,700
Coeptis Pharmaceuticals, Inc. [Member]
Number of generic products \| product				7
Total asset purchase				$ 2,300
Transaction costs				24
Contingent liability not recognized				$ 12,000
Pharmaceutics International, Inc and BAS ANDA LLC [Member]
Payments to Acquire Intangible Assets									$ 500
Finite-Lived Intangible Asset, Useful Life									10 years
Intangible asset impairment charge											0
Teva Pharmaceuticals [Member]
Number of generic products \| product					35
Transaction costs					$ 10
Payments to Acquire Intangible Assets					2,500	$ 16,000
Finite-Lived Intangible Assets, Gross					$ 2,500	9,200
Finite-Lived Intangible Asset, Useful Life					10 years
Intangible asset impairment charge											0
Cumulative Amortization Expense						$ 6,800
Teva Pharmaceuticals [Member] \| Discount rate
Fair Values Inputs Discount Rate					15.00%	12.00%
Impax Laboratories, Inc. [Member]
Number of generic products \| product							2
Transaction costs							$ 100
Payments to Acquire Intangible Assets							2,300
Finite-Lived Intangible Assets, Gross							$ 1,000
Finite-Lived Intangible Asset, Useful Life							10 years
Intangible asset impairment charge											$ 0
Purchase commitment period							17 months
Equipment fair value							$ 58
Property useful life							5 years
Research and Development in Process							$ 1,300
Impax Laboratories, Inc. [Member] \| Discount rate
Fair Values Inputs Discount Rate							75.00%
Impax Laboratories, Inc. [Member] \| Discount rate \| Minimum
Fair Values Inputs Discount Rate							10.00%
Impax Laboratories, Inc. [Member] \| Discount rate \| Maximum
Fair Values Inputs Discount Rate							15.00%
Impax Laboratories, Inc. [Member] \| Milestone One [Member]
Contingent liability not recognized							$ 25,000
Impax Laboratories, Inc. [Member] \| Milestone Two [Member]
Contingent liability not recognized							15,000
Impax Laboratories, Inc. [Member] \| Milestone Three [Member]
Contingent liability not recognized							$ 10,000